Stockscreener 앱 받기
14.55
2.68%
-0.40
시간 외 거래:
15.00
0.45
+3.09%
Artelo Biosciences Inc 주식(ARTL)의 최신 뉴스
What analysts say about Artelo Biosciences Inc. stockExplosive portfolio gains - jammulinksnews.com
What drives Artelo Biosciences Inc. stock priceFree Trend-Following Techniques - Autocar Professional
Artelo Biosciences Announces $6.5 Million At-The-Market Offering Agreement - AInvest
Artelo Biosciences Inc. Stock Analysis and ForecastOutstanding stock performance - Autocar Professional
Is Artelo Biosciences Inc. a good long term investmentFree Stock Market Real-Time Monitoring - jammulinksnews.com
Artelo Biosciences' ATM Offering: A Delicate Balance Between Liquidity and Dilution - AInvest
Artelo Biosciences Announces At-The-Market Offering Agreement - TipRanks
What analysts say about Artelo Biosciences Inc. stock outlookMinimized Risk Maximum Return - Newser
Why Artelo Biosciences Inc. stock attracts strong analyst attentionFree Join Group - Newser
How Artelo Biosciences Inc. stock performs during market volatilityFree Smart Money Stock Analysis - Newser
What makes Artelo Biosciences Inc. stock price move sharplySteady Income Ideas - Newser
Artelo Biosciences Plummets Over 22%—What's Driving the Freefall? - AInvest
Artelo Biosciences Stock Soars 114% After Promising Depression Treatment Data - MSN
Artelo Biosciences Shares Climb on Promising Preclinical Osteoarthritis Pain Data - MSN
Artelo Biosciences Plans to Offer 920K Shares of Common Stock - AInvest
Artelo Biosciences completes reverse stock split and reports preliminary Q2 financials - Investing.com Nigeria
D. Boral Capital Upgrades Artelo Biosciences (NASDAQ:ARTL) to Buy - Defense World
D Boral Capital Upgrades Artelo Biosciences (NASDAQ:ARTL) to Strong-Buy - Defense World
Artelo Biosciences presents positive data for arthritis pain drug By Investing.com - Investing.com South Africa
Artelo Biosciences stock soars after positive preclinical pain data By Investing.com - Investing.com Nigeria
Artelo Biosciences stock soars after positive preclinical pain data - Investing.com
Artelo Biosciences Announces Positive Preclinical Efficacy Data for Art26.12 in Osteoarthritis Pain At the 35Th Annual International Cannabinoid Research Society Symposium - MarketScreener
Artelo Biosciences announces preclinical efficacy results of ART26.12 - TipRanks
Artelo Biosciences Soars 30.5% on Promising Depression Drug Data - AInvest
Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium - The Manila Times
Artelo Biosciences presents positive data for arthritis pain drug - Investing.com
Artelo Biosciences Presents Preclinical Data on ART26.12 as Potential Non-Opioid Treatment for Osteoarthritis Pain at ICRS Symposium - Quiver Quantitative
Breakthrough Pain Drug Matches Naproxen Efficacy Without Opioid Side Effects in Latest Trial - Stock Titan
Artelo Biosciences’ ART12.11 Shows Promising Antidepressant Effects in Preclinical Study - Insider Monkey
Artelo Biosciences Soars 12.26% on Positive Drug Data - AInvest
Artelo Biosciences Analyst See It As An Emerging Biotech - Benzinga
Artelo Biosciences upgraded to Buy from Hold at D. Boral Capital - TipRanks
Artelo Biosciences (NASDAQ:ARTL) Stock Price Up 42.5% – Still a Buy? - Defense World
Artelo Biosciences Soars 6.84% on Promising Depression Drug Data - AInvest
0.87%
0.17%
자본화:
|
볼륨(24시간):